AML ETO t(8;21) Gene Rearrangement Quantitative MRD Monitor Test
Comprehensive Introduction to MRD Monitoring in AML
The AML ETO t(8;21) Gene Rearrangement Quantitative MRD Monitor Test represents a breakthrough in leukemia management and monitoring. This advanced molecular diagnostic test utilizes cutting-edge Real-Time PCR technology to detect and quantify minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) who carry the specific t(8;21) chromosomal translocation. MRD refers to the small number of cancer cells that remain in the body after treatment, which are undetectable by conventional microscopy but can lead to disease relapse if not properly monitored.
This test is particularly crucial because the t(8;21) translocation creates a fusion gene between the RUNX1 gene on chromosome 21 and the RUNX1T1 (ETO) gene on chromosome 8. This genetic abnormality defines a specific subtype of AML that responds well to certain treatments but requires careful monitoring to prevent relapse. The quantitative nature of this test allows hematologists to track disease burden over time, providing invaluable data for treatment decisions and long-term management strategies.
What This Advanced Test Measures and Detects
The AML ETO t(8;21) MRD Monitor Test specifically targets and quantifies the fusion transcript resulting from the chromosomal translocation between chromosomes 8 and 21. This sophisticated molecular assay provides:
- Detection of the AML1-ETO fusion transcript at extremely low levels
- Quantitative measurement of residual leukemia cells
- Sensitivity capable of detecting one leukemia cell among 10,000 normal cells
- Longitudinal monitoring of disease burden throughout treatment
- Early identification of molecular relapse before clinical symptoms appear
Technical Specifications
This test employs Real-Time Quantitative PCR (RQ-PCR) technology, which amplifies and detects the specific fusion gene sequence. The assay is calibrated to provide accurate quantification across a wide dynamic range, from high disease burden to minimal residual levels. The test requires comparison with baseline samples to establish individual patient-specific monitoring thresholds.
Who Should Consider This Essential Monitoring Test
This specialized MRD monitoring test is recommended for specific patient populations under the guidance of hematology specialists:
- Patients with confirmed AML carrying the t(8;21) translocation
- Individuals undergoing or completing chemotherapy treatment for AML
- Patients in clinical remission who require ongoing disease monitoring
- Those with previous history of AML ETO t(8;21) positive disease
- Patients being considered for treatment intensification or reduction
- Individuals participating in clinical trials for AML therapies
Clinical Indications for Testing
Regular MRD monitoring is typically scheduled at specific time points during and after treatment, including:
- After induction chemotherapy to assess initial response
- During consolidation therapy to monitor treatment effectiveness
- At regular intervals during maintenance therapy
- When clinical symptoms suggest possible relapse
- As part of routine long-term follow-up care
Significant Benefits of MRD Monitoring
Undergoing regular AML ETO t(8;21) MRD monitoring provides numerous clinical advantages that can significantly impact treatment outcomes and quality of life:
- Early Relapse Detection: Identifies molecular relapse months before clinical symptoms appear, allowing for timely intervention
- Treatment Guidance: Helps physicians make informed decisions about treatment intensity and duration
- Personalized Medicine: Enables tailored treatment approaches based on individual disease dynamics
- Improved Survival Rates: Early intervention based on MRD results can lead to better long-term outcomes
- Reduced Treatment Toxicity: May allow for treatment de-escalation in patients with sustained MRD negativity
- Peace of Mind: Provides objective data about disease status during remission
Understanding Your Test Results
Interpreting AML ETO t(8;21) MRD results requires careful consideration by your hematology team, but general guidance includes:
MRD Negative Results
A negative result indicates that the fusion transcript was not detected at the assay’s sensitivity level. This typically suggests:
- Successful treatment response
- Continued clinical remission
- Favorable prognosis
- May allow for continued current treatment plan
MRD Positive Results
A positive result indicates detectable levels of the fusion transcript, which may signify:
- Persistent disease despite treatment
- Early molecular relapse
- Need for treatment modification
- Consideration of alternative therapies
Quantitative Interpretation
The quantitative nature of this test allows for tracking changes in MRD levels over time. Rising levels typically indicate disease progression, while decreasing or stable low levels suggest treatment effectiveness. Your hematologist will interpret these trends in the context of your overall clinical picture.
Test Pricing and Availability
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $188 |
| Regular Price | $250 |
Turnaround Time and Sample Requirements
Turnaround: Samples accepted Monday and Thursday by 11 AM; Reports delivered Wednesday and Saturday
Sample Type: 5 mL (3 mL minimum) whole blood or bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.
Mandatory Requirement: Duly filled MRD Requisition form (Form 22) with historical data is mandatory for accurate interpretation.
Nationwide Availability Across the United States
We proudly serve patients across the entire United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our network of certified collection centers ensures accessible testing no matter where you’re located.
Take Control of Your Leukemia Management Today
Don’t leave your leukemia monitoring to chance. The AML ETO t(8;21) Quantitative MRD Monitor Test provides the precise, sensitive monitoring needed for optimal disease management. Early detection of molecular relapse can make a significant difference in treatment outcomes and quality of life.
Ready to schedule your test? Contact our dedicated patient care team today:
Call or WhatsApp: +1(267) 388-9828
Our experienced healthcare professionals are available to answer your questions, assist with scheduling, and provide guidance on preparation requirements. Take the next step in comprehensive leukemia care and book your AML ETO t(8;21) MRD Monitor Test today.
